ImmunityBio, ANKTIVA, Nogapendekin Alfa Inbakicept, Bladder Cancer, NMIBC, BCG-Unresponsive Bladder Cancer, Carcinoma in Situ, QUILT-3.032, Phase 3 Data,

CULVER CITY, Calif., October 16, 2026 ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, announced the publication of long-term...